Navigation Links
African-Americans with blood cancer do not live as long as Caucasians, despite equal care
Date:7/8/2013

A new analysis has found that among patients with chronic lymphocytic leukemia, African Americans more commonly present with advanced disease, and they tend to have shorter survival times than Caucasians despite receiving the same care. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results suggest that biological factors may account for some racial disparities in cancer survival.

Among cancer patients, minorities tend to have a worse prognosis than Caucasians for reasons that are unclear. In African American patients, lower socioeconomic status and limited access to high-quality care often can play a role, but some researchers propose that certain cancers can behave more aggressively in minority individuals, which also can lead to worse outcomes.

Because chronic lymphocytic leukemia (CLL), a type of blood cancer, is rare in African Americans, investigators from The University of Texas MD Anderson Cancer Center in Houston and the Duke University Medical Center in Durham led a study that combined the two centers' experiences with African American and Caucasian patients. Their analysis included 84 African American patients and 1,571 non-black patients referred to the two centers. All patients, regardless of race, had access to healthcare services and received the same treatments. "We sought to isolate race as a prognostic factor from other known demographic and clinical prognostic parameters in CLL," explained Dr. Falchi.

The investigators found that while the time from diagnosis (made either incidentally or because of clinical symptoms) to referral was shorter for African Americans than Caucasian patients, African Americans were more likely to have CLL that was more advanced at the time of referral. Also, although African Americans responded as well to first-line therapy as Caucasian patients, their cancer progressed more rapidly and their survival was shorter. The inferior survival of African American patients persisted when patients were grouped according to factors related to the severity of their disease.

"These findings suggest that while inducing similarly high response rates, standard treatments do not overcome racial differences in outcome among patients with CLL," said Dr. Ferrajoli. She added that a number of questions remain unanswered. For example, do distinct biologic characteristics of African American patients with CLL account for the disparities seen in this study? And will these findings hold in the general population, where the impact of socioeconomic status may be more varied?

In an accompanying editorial, Christopher Flowers, MD, of Emory University in Atlanta, and Barbara Pro, MD, of Thomas Jefferson University in Philadelphia, noted that to adequately study disparities in leukemia, investigators will need to collect specimens and clinical data from patients to examine the potential impact of molecular and biologic markers. "Future studies in CLL can use this work as a cornerstone for investigating racial disparities in this disease," they wrote.


'/>"/>

Contact: Ben Norman
sciencenewsroom@wiley.com
44-012-437-70375
Wiley
Source:Eurekalert

Related medicine news :

1. Age-related smelling loss significantly worse in African-Americans
2. African-Americans experience longer delays between diagnosis and treatment of prostate cancer
3. Vitamin D may lower blood pressure in African-Americans
4. UC research examines interventions in treating African-Americans with substance abuse
5. Exercise linked with reduced prostate cancer risk in Caucasians but not African-Americans
6. Blood pressure diet works, but adherence drops among African-Americans
7. HPV improves survival for African-Americans with throat cancer
8. WSU study finds overwhelming evidence of hidden heart disease in hypertensive African-Americans
9. African Americans with blood cancer do not live as long as caucasians, despite equal care
10. DNA particles in the blood may help speed detection of coronary artery disease
11. New red blood simulator invented at Queen Mary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Atlanta, Georgia (PRWEB) , ... January 19, 2017 ... ... Reconstructive Surgeons hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of ... latest advancements in breast surgery. Covering topics from cosmetic breast augmentation ...
(Date:1/18/2017)... , ... January 18, 2017 , ... A recent video ... a global discussion about the benefits of fidgeting to relieve stress and anxiety. ... Daniel. Their Think Ink Pen had just completed a successful Kickstarter campaign raising ...
(Date:1/18/2017)... LAUDERDALE, FL (PRWEB) , ... January 18, 2017 ... ... how to manage it from the number one doctor-recommended OTC antiperspirant, Certain Dri. ... and often go untreated. , Certain Dri created this infographic to explain the ...
(Date:1/18/2017)... NJ (PRWEB) , ... January ... ... the specialty pharmacy industry’s leading journal and most-read publication among specialty pharmacists ... University Medical Center through its Strategic Alliance Partnership (SAP) program, announced Brian ...
(Date:1/18/2017)... ... 18, 2017 , ... PrideStaff, a national, franchised staffing ... Paula Turner Pizarro, was recently featured on Fox Business Network's Worldwide Business with ... business leaders from across the globe, provides viewers an opportunity to find solutions ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 /PRNewswire/ ... Research, titled, "Breast Imaging Technologies Market by Type: Global Opportunity ... imaging technologies market size was valued at $2,544 million in ... growing at a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in ...
(Date:1/18/2017)... Jan. 18, 2017   Regenicin, Inc. (OTC ... specializing in the development and commercialization of regenerative cell ... organs, recently reported the Company,s operating results for 2016 ... As the Company described in its recent 10-K ... of substantial accomplishments. The Company,s contract laboratory completed its ...
Breaking Medicine Technology: